Soligenix to Present HyBryte Data at USCLC Workshop Ahead of AAD Meeting

Soligenix (SNGX) will present new trial data for HyBryte(TM) at the USCLC Workshop ahead of the American Academy of Dermatology Annual Meeting. The data highlights positive results from a long-term treatment study and a comparative analysis versus Valchlor(R), supporting HyBryte(TM) as a potential therapeutic option for cutaneous T-cell lymphoma. Soligenix is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need.